Therapeutic Strategies in CTVT: Optimizing Outcomes Through Evidence-Based Approaches

Canine Transmissible Venereal Tumour (CTVT) presents a unique therapeutic challenge due to its contagious nature, varied clinical presentation, and potential for recurrence. Over the years, multiple treatment modalities have been explored, including surgery, radiotherapy, chemotherapy, immunotherapy, and biotherapy. However, in routine clinical practice, chemotherapy remains the most preferred and effective approach, especially in generalized or inaccessible lesions^1,2. 

A clear understanding of available therapies and their practical implications is essential for veterinarians to ensure optimal patient outcomes. 

Chemotherapy: The Cornerstone of Treatment 

Among all therapeutic options, vincristine sulphate has consistently demonstrated the highest efficacy and safety, making it the drug of choice in CTVT management ³. It acts by inhibiting mitosis at the metaphase stage, thereby preventing tumour cell proliferation. 

Clinically, vincristine offers rapid and visible results. Bleeding from the tumour typically subsides within 3–4 days after the first dose. By the second administration, a significant reduction in tumour size is observed, and complete remission is usually achieved after a series of weekly injections⁴. This predictable response pattern makes vincristine highly reliable in day-to-day veterinary practice. 

Dosing Considerations: Balancing Efficacy and Safety¹ 

An important yet often overlooked aspect of vincristine therapy is dose calculation. While it is recommended to calculate dosage based on body surface area (BSA), many practitioners use body weight (BW) in clinical settings. 

Evidence suggests that for dogs weighing less than 24 kg, BW-based dosing results in lower drug exposure compared to BSA-based calculations, thereby reducing the risk of toxicity. Conversely, in dogs weighing more than 24 kg, BSA-based dosing may be safer, as BW-based calculations can exceed optimal therapeutic limits. This insight is particularly valuable in preventing overdosing and minimizing adverse effects. 

Role of Other Therapeutic Modalities 

Although chemotherapy dominates treatment protocols, other modalities play supportive or alternative roles depending on the clinical scenario. 

Surgical Intervention 

Surgery, including electrosurgery and cryosurgery, can be effective in localized tumours. However, it is not recommended as a standalone treatment in diffuse cases due to a relatively high recurrence rate of approximately 30%. Combining surgery with chemotherapy significantly improves outcomes¹. 

Radiotherapy 

Radiotherapy offers nearly 100% efficacy and is particularly useful when chemotherapy is not feasible due to logistical or patient-related constraints. It involves the use of ionizing radiation, with recommended doses ranging from 1500 to 2500 rads¹. 

Immunotherapy and Biotherapy 

Emerging therapies focus on enhancing the host immune response. Approaches include the use of interleukin-2 (IL-2), tumour-derived exosomes, and even whole blood or serum transfusions from recovered animals^1,5. These are especially beneficial in immunocompromised patients. 

Alternative Chemotherapeutic Agents 

While vincristine remains the gold standard, alternative agents such as cyclophosphamide, vinblastine, doxorubicin, and methotrexate have been explored, either as single agents or in combination protocols. These alternatives are particularly relevant in cases where vincristine is contraindicated or ineffective⁶. 

However, it is important to note that existing evidence does not demonstrate a significant advantage of combination chemotherapy over vincristine monotherapy in routine cases¹. 

Clinical Takeaway 

For practicing veterinarians, the management of CTVT should be individualized based on tumour extent, patient condition, and treatment response. Vincristine sulphate remains the most effective and practical first-line therapy, but knowledge of adjunct and alternative modalities is crucial for handling complex cases. 

A strategic approach that integrates correct dosing, timely monitoring, and appropriate use of supportive therapies can significantly enhance treatment success while minimizing complications. 

Reference 

1. Biswas N, Singh K, Kumar S, Parmar S, Srivastava N, Khan MH. Therapeutics and Management of Persistent Cases of Canine Transmissible Venereal Tumour: An Update. Animal Reproduction Update. 2024 Jul 1;4(2). https://www.researchgate.net/profile/Newton-Biswas/publication/381583366_Therapeutics_and_Management_of_Persistent_Cases_of_Canine_Transmissible_Venereal_Tumour_An_Update/links/667537771846ca33b842ba3a/Therapeutics-and-Management-of-Persistent-Cases-of-Canine-Transmissible-Venereal-Tumour-An-Update.pdf 

2. Parikh NP, Panchal MT, Parmar JJ, Ghodasara DJ. Therapeutic management of transmissible venereal tumour in dogs.  Indian J Vet Sci. 2023; 19(4): 78-83. https://www.researchgate.net/profile/Jignesh-Parmar/publication/373196873_Therapeutic_Management_of_Transmissible_Venereal_Tumour_in_Dogs/links/64df855c14f8d173380a5672/Therapeutic-Management-of-Transmissible-Venereal-Tumour-in-Dogs.pdf 

3. Reis Filho NP, Torres AA, Silva MP, Ventura RF, Basso KM, Ferreira MG, De Nardi AB, Floriano BP, Calderón C. Transmissible venereal tumor: cell proliferation (agnor) and response to chemotherapy correlated with cytomorphological classification. Ars Veterinaria. 2020 Jun 25;36(2):140-7. https://www.arsveterinaria.org.br/index.php/ars/article/download/1247/2040 

4. Arunpandian J, Neethu B, Srivastava N, Kujur A, Aswinisivan G. Successful therapeutic management of canine transmissible venereal tumour in native breed dogs of TamilNadu. Indian J Anim Reprod. 2021; 42(1): 56-57. https://www.researchgate.net/profile/Newton-Biswas/publication/381583366_Therapeutics_and_Management_of_Persistent_Cases_of_Canine_Transmissible_Venereal_Tumour_An_Update/links/667537771846ca33b842ba3a/Therapeutics-and-Management-of-Persistent-Cases-of-Canine-Transmissible-Venereal-Tumour-An-Update.pdf 

5. Ramos-Zayas Y, Franco-Molina MA, Hernádez-Granados AJ, Zárate-Triviño DG, Coronado-Cerda EE, MendozaGamboa E, Zapata-Benavides P, Ramírez-Romero R, Santana-Krymskaya SE, Tamez-Guerra R, RodríguezPadilla C. Immunotherapy for the treatment of canine transmissible venereal tumor based in dendritic cells pulsed with tumoral exosomes. Immunopharmacol Immunotoxicol. 2019;41(1):48-54. Doi: 10.1080/08923973.2018.1533969. https://www.academia.edu/download/89950449/08923973.2018.153396920220819-1-1dpj2lb.pdf 
6. Sewoyo PS, Kardena IM. Canine transmissible venereal tumor: treatment review and updates.  Rev Electron Vet. 2022; 23(1): 01-07. https://www.researchgate.net/profile/Palagan-Sewoyo/publication/358200686_Canine_Transmissible_Venereal_Tumor_Treatment_Review_and_Updates/links/61f51f24007fb5044720c780/Canine-Transmissible-Venereal-Tumor-Treatment-Review-and-Updates.pdf